TRACON Pharmaceuticals
Market Cap
US$138.8m
Last Updated
2021/01/21 23:41 UTC
Data Sources
Company Financials +
Executive Summary
TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). More Details
Rewards
Risk Analysis
Shareholders have been substantially diluted in the past year
Currently unprofitable and not forecast to become profitable over the next 3 years
+ 1 more risk
Snowflake Analysis
Adequate balance sheet with weak fundamentals.
Share Price & News
How has TRACON Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TCON is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: TCON's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
Market Performance
7 Day Return
-9.1%
TCON
0.7%
US Biotechs
1.4%
US Market
1 Year Return
131.5%
TCON
40.9%
US Biotechs
22.6%
US Market
Return vs Industry: TCON exceeded the US Biotechs industry which returned 41.5% over the past year.
Return vs Market: TCON exceeded the US Market which returned 22.8% over the past year.
Shareholder returns
| TCON | Industry | Market | |
|---|---|---|---|
| 7 Day | -9.1% | 0.7% | 1.4% |
| 30 Day | 13.3% | 5.2% | 4.9% |
| 90 Day | 105.3% | 23.7% | 14.6% |
| 1 Year | 131.5%131.5% | 43.2%40.9% | 25.4%22.6% |
| 3 Year | -65.3%-65.3% | 27.1%20.5% | 46.8%37.0% |
| 5 Year | -86.7%-86.7% | 58.4%46.0% | 132.0%106.1% |
Long-Term Price Volatility Vs. Market
How volatile is TRACON Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall St
Introducing TRACON Pharmaceuticals (NASDAQ:TCON), The Stock That Tanked 92%1 year ago | Simply Wall St
Introducing TRACON Pharmaceuticals (NASDAQ:TCON), The Stock That Tanked 92%1 year ago | Simply Wall St
What Kind Of Shareholder Appears On The TRACON Pharmaceuticals, Inc.'s (NASDAQ:TCON) Shareholder Register?Valuation
Is TRACON Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
8.96x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate TCON's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate TCON's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: TCON is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: TCON is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TCON's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TCON is overvalued based on its PB Ratio (9x) compared to the US Biotechs industry average (4.5x).
Next Steps
Future Growth
How is TRACON Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
38.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TCON is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TCON is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TCON is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TCON is forecast to have no revenue next year.
High Growth Revenue: TCON is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TCON's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has TRACON Pharmaceuticals performed over the past 5 years?
2.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TCON is currently unprofitable.
Growing Profit Margin: TCON is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TCON is unprofitable, but has reduced losses over the past 5 years at a rate of 2.3% per year.
Accelerating Growth: Unable to compare TCON's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TCON is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).
Return on Equity
High ROE: TCON has a negative Return on Equity (-105.9%), as it is currently unprofitable.
Next Steps
Financial Health
How is TRACON Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: TCON's short term assets ($27.5M) exceed its short term liabilities ($10.0M).
Long Term Liabilities: TCON's short term assets ($27.5M) exceed its long term liabilities ($2.6M).
Debt to Equity History and Analysis
Debt Level: TCON's debt to equity ratio (23.9%) is considered satisfactory.
Reducing Debt: TCON's debt to equity ratio has increased from 17.1% to 23.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TCON has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: TCON has less than a year of cash runway if free cash flow continues to reduce at historical rates of 12.8% each year
Next Steps
Dividend
What is TRACON Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TCON's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TCON's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TCON's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TCON's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TCON's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.3yrs
Average management tenure
CEO
Charles Theuer (56 yo)
14.58yrs
Tenure
US$1,085,324
Compensation
Dr. Charles P. Theuer, M.D., Ph.D., has been the President and Chief Executive Officer of Tracon Pharmaceuticals, Inc. since June 2006 and has been its Director of Tracon Pharmaceuticals, Inc. since June 2...
CEO Compensation Analysis
Compensation vs Market: Charles's total compensation ($USD1.09M) is above average for companies of similar size in the US market ($USD533.25K).
Compensation vs Earnings: Charles's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 14.58yrs | US$1.09m | 1.39% $ 1.9m | |
| Chief Accounting Officer & Head of Finance | 2yrs | US$501.25k | 0.010% $ 14.5k | |
| Chief Business Officer | 2.67yrs | US$603.02k | 0.10% $ 138.9k | |
| Executive Vice President of Clinical Operations | 6.5yrs | no data | no data | |
| Senior VP & Head of Quality Assurance | 1yr | no data | no data | |
| Chief Medical Officer | 0.67yr | no data | no data |
2.3yrs
Average Tenure
56yo
Average Age
Experienced Management: TCON's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 14.58yrs | US$1.09m | 1.39% $ 1.9m | |
| Independent Director | 5.92yrs | US$73.63k | 0.0055% $ 7.6k | |
| Independent Director | 6.5yrs | US$61.75k | 0.0098% $ 13.6k | |
| Independent Director | 6.08yrs | US$55.50k | 0.0055% $ 7.6k | |
| Independent Director | 0.83yr | no data | 0.040% $ 55.8k | |
| Independent Director | 12.33yrs | US$46.75k | 0.0055% $ 7.6k | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | 4.08yrs | no data | no data |
6.1yrs
Average Tenure
62yo
Average Age
Experienced Board: TCON's board of directors are considered experienced (6.1 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: TCON insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 233.8%.
Top Shareholders
Company Information
TRACON Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: TRACON Pharmaceuticals, Inc.
- Ticker: TCON
- Exchange: NasdaqCM
- Founded: 2004
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$138.763m
- Shares outstanding: 13.68m
- Website: https://www.traconpharma.com
Number of Employees
Location
- TRACON Pharmaceuticals, Inc.
- 4350 La Jolla Village Drive
- Suite 800
- San Diego
- California
- 92122
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| TCON | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Jan 2015 |
| T051 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jan 2015 |
Biography
TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lea...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/21 23:41 |
| End of Day Share Price | 2021/01/21 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.